Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
AbstractPurpose of ReviewObesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology.Recent FindingsOrlistat and some glucagon-like peptide-1 receptor analogs, including liraglutide and semaglutide, have beneficial effects on hepatic steatosis and inflammation, but not fibrosis. Other anti-obesity medications, including lorcaserin, setmelanotide, phentermine hydrochloric, phentermine/topiramate, and nalt...
Source: Current Obesity Reports - May 2, 2022 Category: Eating Disorders & Weight Management Source Type: research
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review
CONCLUSIONS: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity.PMID:35333446 | DOI:10.1002/oby.23371 (Source: Obesity)
Source: Obesity - March 25, 2022 Category: Eating Disorders & Weight Management Authors: Abd A Tahrani John Morton Source Type: research
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review
CONCLUSIONS: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity.PMID:35333446 | DOI:10.1002/oby.23371 (Source: Obesity)
Source: Obesity - March 25, 2022 Category: Eating Disorders & Weight Management Authors: Abd A Tahrani John Morton Source Type: research
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review
CONCLUSIONS: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity.PMID:35333446 | DOI:10.1002/oby.23371 (Source: Obesity)
Source: Obesity - March 25, 2022 Category: Eating Disorders & Weight Management Authors: Abd A Tahrani John Morton Source Type: research
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review
CONCLUSIONS: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity.PMID:35333446 | DOI:10.1002/oby.23371 (Source: Obesity)
Source: Obesity - March 25, 2022 Category: Eating Disorders & Weight Management Authors: Abd A Tahrani John Morton Source Type: research
The Effect of Orlistat on Sterol Metabolism in Obese Patients
CONCLUSION: Orlistat treatment improves oxysterol metabolism in overweight and obese adults. Our findings support that orlistat plays a crucial role in the process of endothelial dysfunction and atherosclerosis via oxysterol modulation.PMID:35282441 | PMC:PMC8905288 | DOI:10.3389/fendo.2022.824269 (Source: Atherosclerosis)
Source: Atherosclerosis - March 14, 2022 Category: Cardiology Authors: Yu-Jin Kwon Go Eun Kwon Hye Sun Lee Man Ho Choi Ji-Won Lee Source Type: research
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
Conclusions
Once-daily vibegron had no statistically significant or clinically relevant effects on BP or HR. (Source: Blood Pressure Monitoring)
Source: Blood Pressure Monitoring - March 8, 2022 Category: Cardiology Tags: Devices and Technology Source Type: research
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk
Metabolic risk for cardiovascular and other systems includes much more than just LDL cholesterol. This JCL Roundtable brings together 3 experts to address new opportunities to reduce the risks posed by obesity, diabetes, and fatty liver disease. Successful nutritional approaches to weight loss are diverse and need to be matched with individual preferences. Topiramate plus extended-release phentermine has been shown to promote meaningful weight loss in randomized trials, but the patented drug combination is expensive. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 1, 2022 Category: Lipidology Authors: Kathleen L. Wyne, Sheldon E. Litwin, Kenneth Cusi, John R. Guyton Source Type: research
Weight gain after in vitro fertilization: a potential consequence of controlled ovarian stimulation
AbstractIn the USA, 42% of adult women were estimated to have obesity, and 13% of women of childbearing age similarly have impaired fecundity. Obesity is associated with infertility such that patients with obesity often seek out in vitro fertilization (IVF) services. Here, we report on the case of a woman with childhood-onset class II obesity who had been undergoing treatment with phentermine and topiramate prior to undergoing 3 cycles of IVF. With each cycle, the patient temporarily gained 13 –15 lbs. during controlled ovarian stimulation (COS). Weight gain from COS may be clinically relevant and merits further study to...
Source: Journal of Assisted Reproduction and Genetics - February 26, 2022 Category: Reproduction Medicine Source Type: research
The Effect of Orlistat on Sterol Metabolism in Obese Patients
ConclusionOrlistat treatment improves oxysterol metabolism in overweight and obese adults. Our findings support that orlistat plays a crucial role in the process of endothelial dysfunction and atherosclerosis via oxysterol modulation. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - February 23, 2022 Category: Endocrinology Source Type: research
Discriminative stimulus effects of an imidazolidine-derived appetite suppressant
In this study, GYKI-13380 was tested in rats trained to discriminate injections of eitherS(+)amphetamine (0.75 mg/kg, IP) or fenfluramine (1.5 mg/kg, IP) from saline in a two-lever drug discrimination task. After stable discrimination performances were attained in each group, stimulus generalization (substitution) tests were conducted with GYKI-13380 and currently marketed CNS stimulant/anorectic drugs (phentermine, (−)ephedrine, diethylpropion and phendimetrazine). The fenfluramine stimulus generalized completely to GYKI-13380, but not toS(+)amphetamine nor to the stimulant/anorectic agents. In contrast,S(+)ampheta...
Source: Medicinal Chemistry Research - February 16, 2022 Category: Chemistry Source Type: research
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
AbstractDravet syndrome is a severe developmental and epileptic encephalopathy characterised by refractory seizures and cognitive dysfunction. The treatment is challenging, not least because the seizures are highly drug resistant, requiring multiple anti-seizure medications (ASMs), while some ASMs can exacerbate seizures. Initial treatments include the broad-spectrum ASMs valproate (VPA), and clobazam (CLB) in some regions; however, they are generally insufficient to control seizures. With this in mind, three adjunct ASMs have been approved specifically for the treatment of seizures in patients with Dravet syndrome: stirip...
Source: CNS Drugs - February 14, 2022 Category: Neurology Source Type: research
